Mesoblast Company Profile (NASDAQ:MESO)

About Mesoblast

Mesoblast logoMesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates, which represents its lead programs where it focuses on time and resources, such as MPC-06-ID, MPC-150-IM, JR-031, MPC-300-IV and MSC-100-IV, and tier 2 product candidates, which advances to tier 1 depending on newly-generated data, market opportunity or partnering options, such as MSC-100-IV, MPC-25-IC, MPC-25-Osteo and MPC-CBE.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MESO
  • CUSIP:
Key Metrics:
  • Previous Close: $4.98
  • 50 Day Moving Average: $4.66
  • 200 Day Moving Average: $6.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.05
  • P/E Growth: 0.00
  • Market Cap: $383.91M
  • Outstanding Shares: 75,425,000
  • Beta: 2.95
Additional Links:
Companies Related to Mesoblast:

Analyst Ratings

Consensus Ratings for Mesoblast (NASDAQ:MESO) (?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $8.63 (73.19% upside)

Analysts' Ratings History for Mesoblast (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2016Maxim GroupReiterated RatingBuy$14.00View Rating Details
6/14/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$10.00 -> $5.00View Rating Details
3/7/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$9.00 -> $10.00View Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldView Rating Details
11/24/2015Ladenburg ThalmannReiterated RatingBuyView Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Mesoblast (NASDAQ:MESO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2016Q216($0.06)$30.00 million$4.00 millionViewListenView Earnings Details
12/16/2015Q116($0.04)$7.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mesoblast (NASDAQ:MESO)
Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $-1.23 EPS

Dividends

Dividend History for Mesoblast (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Mesoblast (NASDAQ:MESO)
DateHeadline
reuters.com logoBRIEF-Mesoblast reports Q4 earnings per share $0.1278 (NASDAQ:MESO)
www.reuters.com - August 25 at 11:13 AM
benzinga.com logoMesoblast Reports Financial Results and... (NASDAQ:MESO)
www.benzinga.com - August 25 at 11:13 AM
News IconMesoblast’s MPC: Positive Results (NASDAQ:MESO)
ryortho.com - August 25 at 11:13 AM
investing.com logoMarkets Limp Towards Yellen’s Friday Speech (NASDAQ:MESO)
www.investing.com - August 25 at 11:13 AM
4-traders.com logoMesoblast : Reports on Annual and Fourth Quarter Results (NASDAQ:MESO)
www.4-traders.com - August 25 at 11:13 AM
finance.yahoo.com logoMesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016 (NASDAQ:MESO)
finance.yahoo.com - August 25 at 11:13 AM
publicnow.com logoMesoblast Reports on Annual and Fourth Quarter Results (NASDAQ:MESO)
www.publicnow.com - August 25 at 11:12 AM
publicnow.com logoAnnual Financial Results Presentation (NASDAQ:MESO)
www.publicnow.com - August 25 at 11:12 AM
publicnow.com logoPreliminary Final Report (Including Appendix 4E) (NASDAQ:MESO)
www.publicnow.com - August 25 at 11:12 AM
investorplace.com logoBiggest Movers in Manufacturing Stocks Now - NYMX CORI DXYN MNTA - Investorplace.com (NASDAQ:MESO)
investorplace.com - August 24 at 5:57 PM
benzinga.com logoEarnings Scheduled For August 24, 2016 - Benzinga - Benzinga (NASDAQ:MESO)
www.benzinga.com - August 24 at 9:16 AM
finance.yahoo.com logoMesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast (NASDAQ:MESO)
finance.yahoo.com - August 19 at 9:09 AM
investing.com logoAustralia stocks higher at close of trade; S&P/ASX 200 up 0.11% - Investing.com (NASDAQ:MESO)
www.investing.com - August 18 at 6:13 PM
fool.com logoASX 200 drops: 12 shares you should have been watching | Motley ... - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 18 at 6:13 PM
investors.com logoMesoblast Ltd granted key U.S. patent for treating rheumatic diseases - Proactive Investors Australia (NASDAQ:MESO)
www.proactiveinvestors.com.au - August 18 at 6:13 PM
News IconBone Marrow Transplant Market Segments and Forecast By End-use Industry 2016-2026 (NASDAQ:MESO)
www.medgadget.com - August 18 at 9:15 AM
4-traders.com logoMesoblast : MSB Strengthens US Patent Portfolio For Rheumatic Diseases (NASDAQ:MESO)
www.4-traders.com - August 17 at 9:15 AM
investors.com logoMesoblast Ltd granted key U.S. patent for treating rheumatic diseases (NASDAQ:MESO)
www.proactiveinvestors.com.au - August 17 at 9:15 AM
publicnow.com logoMSB Strengthens US Patent Portfolio For Rheumatic Diseases (NASDAQ:MESO)
www.publicnow.com - August 17 at 9:15 AM
finance.yahoo.com logoMesoblast Strengthens Key United States Patent Portfolio for the Treatment of Rheumatic Diseases (NASDAQ:MESO)
finance.yahoo.com - August 17 at 9:15 AM
finance.yahoo.com logo6:01 am Mesoblast follow-up; granted patent by the USPTO for its intellectual property portfolio covering the use of its Mesenchymal Precursor Cells in the treatment of rheumatic diseases, including rheumatoid arthritis (NASDAQ:MESO)
finance.yahoo.com - August 17 at 9:15 AM
investing.com logoAustralia stocks lower at close of trade; S&P/ASX 200 down 0.12% - Investing.com (NASDAQ:MESO)
www.investing.com - August 16 at 6:16 PM
investorplace.com logoHottest Manufacturing Stocks Now - TOF AUPH LEDS RVP - Investorplace.com (NASDAQ:MESO)
investorplace.com - August 16 at 6:16 PM
fool.com logoASX 200 sinks: 11 shares you should have been watching - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 16 at 6:16 PM
investing.com logoAustralia stocks higher at close of trade; S&P/ASX 200 up 0.25% - Investing.com (NASDAQ:MESO)
www.investing.com - August 15 at 6:22 PM
News IconMesoblast (ASX.MSB) Heffx Trading Outlook - Live Trading News (NASDAQ:MESO)
www.livetradingnews.com - August 15 at 8:19 AM
investing.com logoAustralia shares higher at close of trade; S&P/ASX 200 up 0.24% - Investing.com UK (NASDAQ:MESO)
uk.investing.com - August 15 at 8:19 AM
fool.com logoHere's why these 4 ASX shares have stormed higher today - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 15 at 8:19 AM
fool.com logoASX 200 rises: 10 shares you should have been watching - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 15 at 8:19 AM
fool.com logoHere's why these 4 ASX shares jumped higher today - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 12 at 9:25 AM
smh.com.au logoMarkets Live: ASX battles higher - The Sydney Morning Herald (NASDAQ:MESO)
www.smh.com.au - August 12 at 9:25 AM
investing.com logoAustralia stocks lower at close of trade; S&P/ASX 200 down 0.71% - Investing.com (NASDAQ:MESO)
www.investing.com - August 11 at 6:32 PM
investorplace.com logoBiggest Movers in Manufacturing Stocks Now - KURA AEMD LEDS PRPH - Investorplace.com (NASDAQ:MESO)
investorplace.com - August 11 at 6:32 PM
investing.com logoAustralia shares lower at close of trade; S&P/ASX 200 down 0.72% - Investing.com UK (NASDAQ:MESO)
uk.investing.com - August 11 at 9:21 AM
fool.com logoASX 200 falls sharply: 12 shares you should have been watching - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 11 at 9:21 AM
fool.com logoHere's why beaten down Mesoblast limited is making a comeback - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 11 at 9:21 AM
News IconNew stem-cell treatment shows promise for rheumatoid arthritis patients: report (NASDAQ:MESO)
www.rawstory.com - August 10 at 6:35 PM
News IconNew Mesoblast Stem Cell Therapy in Treating Rheumatoid Arthritis (NASDAQ:MESO)
www.argyllfreepress.com - August 10 at 9:08 AM
fool.com logoHere’s why beaten down Mesoblast limited is making a comeback (NASDAQ:MESO)
www.fool.com.au - August 10 at 9:08 AM
News IconRheumatoid Arthritis May See Relief With Mesoblast Treatment (NASDAQ:MESO)
cdanews.com - August 10 at 9:08 AM
News IconMesoblast’s Stem-Cell Treatment Shows Improvement In Rheumatoid Arthritis Patients (NASDAQ:MESO)
www.ibtimes.com - August 10 at 9:08 AM
foxnews.com logoMesoblast cell treatment shows promise in rheumatoid arthritis, study finds (NASDAQ:MESO)
www.foxnews.com - August 10 at 9:08 AM
News IconImprovements in pain, function seen with intra-disc injection for patients with low back pain - Healio (NASDAQ:MESO)
www.healio.com - August 9 at 6:23 PM
investing.com logoAustralia stocks higher at close of trade; S&P/ASX 200 up 0.29% - Investing.com (NASDAQ:MESO)
www.investing.com - August 9 at 6:23 PM
investing.com logoAustralia shares higher at close of trade; S&P/ASX 200 up 0.29% - Investing.com UK (NASDAQ:MESO)
uk.investing.com - August 9 at 9:15 AM
smh.com.au logoASX gains in whipsaw day as investors digest flood of earnings - The Sydney Morning Herald (NASDAQ:MESO)
www.smh.com.au - August 9 at 9:15 AM
nasdaq.com logoMESO Gains After Hours, PFNX Gets It Back, CHRS' Humira Biosimilar Meets Goals - Nasdaq (NASDAQ:MESO)
www.nasdaq.com - August 9 at 9:15 AM
fool.com logoASX 200 lifts on ANZ report: 11 shares you should have been watching - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 9 at 9:15 AM
reuters.com logoBRIEF-Mesoblast intends to enter into strategic partnership advancing phase 3 development of allogeneic MPCS for ... - Reuters (NASDAQ:MESO)
www.reuters.com - August 9 at 9:15 AM
News IconMesoblast's Stem-Cell Treatment Shows Improvement In Rheumatoid Arthritis Patients - International Business Times (NASDAQ:MESO)
www.ibtimes.com - August 9 at 9:14 AM

Social

Mesoblast (NASDAQ:MESO) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff